Synonyms: 3,4-dihydroxy-L-phenylalanine | Inbrija® (levodopa inhalation powder) | L-DOPA | Sinemet®
levodopa is an approved drug (FDA (1993), EMA (2003))
Compound class:
Metabolite
Comment: L-DOPA is the precursor to the neurotransmitters dopamine collectively known as catecholamines. Used in the treatment of Parkisons disease. Note a deuterated derivative D3 L-DOPA with enhanced properties is under development.
![]() View more information in the IUPHAR Pharmacology Education Project: levodopa |
|
Bioactivity Comments |
Levodopa is a dopamine precursor and has no intrinsic target interactions that convey its therapeutic actions. It acts indirectly by promoting increased dopamine biosynthesis. |
Natural/Endogenous Targets | ||
|
Enzymes Catalysing Reactions with this Compound as a Substrate or Product | ||||||||||||
|
Transporters Moving this Compound Across a Lipid Membrane | ||||||||
|
Selectivity at GPCRs | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
Ligand mentioned in the following text fields |
Catecholamine turnover overview |